UPDATE: Credit Suisse Upgrades Boston Scientific to Outperform on Expected Positive Sales Growth
April 26, 2013 at 12:03 PM EDT
In a report published Friday, Credit Suisse analyst Bruce Nudell upgraded the rating on Boston Scientific Corporation (NYSE: BSX ) from Neutral to Outperform, and slightly raised the price target from $8.50 to $8.75. In the report, Nudell noted, “While there weren't any positive surprises in BSX's results today we
